Coherus BioSciences Inc (CHRS) - Total Liabilities
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has total liabilities worth $197.33 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Coherus BioSciences Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Coherus BioSciences Inc (CHRS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Coherus BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Coherus BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Willy Food
TA:WLFD
|
Israel | ILA65.42 Million |
|
RAINBOW RARE EARTHS LTD
F:RR1
|
Germany | €12.88 Million |
|
Starpharma Holdings Ltd
AU:SPL
|
Australia | AU$4.69 Million |
|
Topco Technologies
TWO:3388
|
Taiwan | NT$1.92 Billion |
|
Meridian Bank
NASDAQ:MRBK
|
USA | $2.38 Billion |
|
Wendell Industrial Co. Ltd
TWO:6761
|
Taiwan | NT$867.74 Million |
|
Gaon Group Ltd
TA:GAGR
|
Israel | ILA619.26 Million |
|
Stoneridge Inc
NYSE:SRI
|
USA | $355.17 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Coherus BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CHRS company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coherus BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coherus BioSciences Inc (2012–2025)
The table below shows the annual total liabilities of Coherus BioSciences Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $197.33 Million | -66.01% |
| 2024-12-31 | $580.52 Million | -29.47% |
| 2023-12-31 | $823.03 Million | +33.12% |
| 2022-12-31 | $618.26 Million | +6.30% |
| 2021-12-31 | $581.61 Million | +3.73% |
| 2020-12-31 | $560.67 Million | +84.61% |
| 2019-12-31 | $303.71 Million | +119.99% |
| 2018-12-31 | $138.06 Million | +4.53% |
| 2017-12-31 | $132.08 Million | -17.00% |
| 2016-12-31 | $159.13 Million | -27.44% |
| 2015-12-31 | $219.31 Million | +82.06% |
| 2014-12-31 | $120.46 Million | +34.10% |
| 2013-12-31 | $89.83 Million | +418.02% |
| 2012-12-31 | $17.34 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more